阿达木单抗治疗药物监测对RA后续bDMARD疗效无预测价值
该回顾性队列研究纳入137例因疗效不佳停用阿达木单抗并换用其他bDMARD的类风湿关节炎患者,评估抗阿达木单抗抗体(ADA)与阿达木单抗血清水平(ADL)对换药后EULAR良好反应的预测价值。结果显示ADA与ADL对换用TNFi或非TNFi的后续治疗均无预测价值,原发与继发无应答者亚组结果相似。
要点
- ADA对换用TNFi或非TNFi的EULAR良好反应均无预测价值。
- 随机时点ADL水平对后续TNFi或非TNFi治疗反应同样无预测价值。
- 原发与继发无应答者中ADA和ADL的预测价值相似。
核心结论
- 与既往研究相反,ADA或随机时点ADL均不能预测RA患者换用第二种TNFi或非TNFi bDMARD后的治疗反应。
研究设计与样本
- 诊断试验准确性回顾性队列研究,纳入137例因疗效不佳停用阿达木单抗(治疗>3个月)并开始另一种bDMARD的RA患者。
- 血清样本要求为阿达木单抗起始后≥8周至停药后≤2周内的随机时点样本,结局为换药后3至6个月的DAS28-CRP。
- 以EULAR良好反应(基于DAS28-CRP)为结局,采用ROC曲线下面积及灵敏度/特异度评估预测效能。
- 对原发和继发无应答者进行亚组分析。
主要发现
- ADA预测换用TNFi后反应的灵敏度/特异度为18%/75%,预测换用非TNFi后为33%/70%。
- ADL预测换用TNFi后反应的灵敏度/特异度为50%/52%,预测换用非TNFi后为32%/69%。
- ADA和ADL在原发与继发无应答者中的预测价值相似。
关键数值与推荐
- EULAR良好反应基于DAS28-CRP评估,于换药后3至6个月判定。
- ADA预测换用TNFi的灵敏度/特异度为18%/75%,换用非TNFi为33%/70%。
- ADL预测换用TNFi的灵敏度/特异度为50%/52%,换用非TNFi为32%/69%。
临床怎么用
- 对于阿达木单抗治疗失败后选择后续bDMARD的RA患者,不应依据ADA或随机时点ADL检测结果来决定换用TNFi还是非TNFi。
- 换药决策仍应基于群体证据与其他临床因素综合判断。
局限性
- 本研究为回顾性队列研究,血清样本为随机时点采集而非固定时间点。
- 样本来自单一批同意患者,可能存在选择偏倚。
- 仅评估EULAR良好反应,未涉及其他疗效结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After adalimumab treatment failure, tumour necrosis factor inhibition (TNFi) and non-TNFi biological disease-modifying anti-rheumatic drugs (bDMARDs) are equally viable options on a group level as subsequent treatment in rheumatoid arthritis (RA) based on the current best evidence synthesis. However, preliminary data suggest that anti-adalimumab antibodies (anti-drug antibodies, ADA) and adalimumab serum levels (ADL) during treatment predict response to a TNFi as subsequent treatment. OBJECTIVE: To validate the association of presence of ADA and/or low ADL with response to a subsequent TNFi bDMARD or non-TNFi bDMARD. Sub-analyses were performed for primary and secondary non-responders. METHODS: A diagnostic test accuracy retrospective cohort study was done in consenting RA patients who discontinued adalimumab after >3 months of treatment due to inefficacy and started another bDMARD. Inclusion criteria included the availability of (random timed) serum samples between ≥8 weeks after start and ≤2 weeks after discontinuation of adalimumab, and clinical outcome measurements Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) between 3 to 6 months after treatment switch. Test characteristics for EULAR (European League Against Rheumatism) good response (DAS28-CRP based) after treatment with the next (non-)TNFi bDMARD were assessed using area under the receiver operating characteristic and sensitivity/specificity. RESULTS: 137 patients were included. ADA presence was not predictive for response in switchers to a TNFi (sensitivity/specificity 18%/75%) or a non-TNFi (sensitivity/specificity 33%/70%). The same was true for ADL levels in patients that switched to a TNFi (sensitivity/specificity 50%/52%) and patients that switched to a non-TNFi (sensitivity/specificity 32%/69%). Predictive value of ADA and ADL were similar for both primary and secondary non-responders to adalimumab. CONCLUSIONS: In contrast to earlier research, we could not find predictive value for response to a second TNFi or non-TNFi for either ADA or random timed ADL.
引用
- Ulijn E, den Broeder N, Wientjes M, et al. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. Ann Rheum Dis. 2020. PMID: 32317314. doi:10.1136/annrheumdis-2020-216996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。